Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Maruho Exec Requests Discussions on Proper Use of Heparinoid Agents Based on “Appropriate Data,” Calls for Detailed Analysis of NDB
November 17, 2017
- Adcetris Gets European Panel Backing for CTCL: Takeda
November 16, 2017
- Transfer of LLPs from Chugai “Our Ticket to Admission” into Pharma Business: Taiyo Pharma COO
November 16, 2017
- FDA Approves Sensor-Embedded Abilify, World’s 1st Digital Pill
November 15, 2017
- Chugai to Offload 13 Off-Patent Brands to Taiyo Holdings
November 15, 2017
- Fujifilm Invests in Tsukuba-Based Upstart, Grabs Transgenic Technologies for iPS Cell Production
November 14, 2017
- Reported Off-Patent Drug Divestment “Not Based on Announcement”: Chugai
November 14, 2017
- Harvoni Drops Out of Top 10 Product List in Japan in June-September: IQVIA
November 13, 2017
- Ethical Drug Sales Up 0.7% in September; 1st DPP-4/SGLT2 Combo Upbeat: Crecon
November 10, 2017
- Takeda’s Relugolix Hits Primary Endpoint in Uterine Fibroids-Tied Pain: Japan PIII
November 10, 2017
- Ono Links Arms with Neurimmune on Neurodegenerative Disease
November 10, 2017
- Gilead’s VP for EMEA Hermans to Replace Orihara as Japan Head
November 10, 2017
- Can Japan’s 1st Enbrel Biosimilar Make Its Mark in RA Follow-On Arena with Self-Injection?
November 10, 2017
- Kyorin Pres. Says AG Strategy Is a “Success,” Nasonex Eyed as 2nd Battlefield
November 9, 2017
- Takata Seiyaku to Take Over MA for MSD’s Gentacin
November 9, 2017
- Mitsubishi Tanabe Grabs Distribution Rights to Clenafin/Jublia in Taiwan
November 9, 2017
- Top Court Dismisses Elplat Patent Infringement Case: Nichi-Iko
November 9, 2017
- Takeda Teams Up with US Medical Device Company to Develop Needle-Free Injection Device Utilizing Pressurized Liquid
November 9, 2017
- Evocalcet Shows Non-Inferiority to Regpara in Japan PIII
November 8, 2017
- Tolvaptan Re-Submitted to US FDA for ADPKD: Otsuka
November 8, 2017
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…